Attached files
| file | filename |
|---|---|
| 10-K - FORM 10-K - Biostage, Inc. | v435009_10k.htm |
| EX-32.2 - EXHIBIT 32.2 - Biostage, Inc. | v435009_ex32-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Biostage, Inc. | v435009_ex31-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Biostage, Inc. | v435009_ex31-2.htm |
| EX-21.1 - EXHIBIT 21.1 - Biostage, Inc. | v435009_ex21-1.htm |
| EX-32.1 - EXHIBIT 32.1 - Biostage, Inc. | v435009_ex32-1.htm |
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Harvard Apparatus Regenerative Technology, Inc.:
We consent to the incorporation by reference in the Registration Statement No. 333-200926 of Harvard Apparatus Regenerative Technology, Inc. on Form S-3 and Registration Statement Nos. 333-192026 and 333-192027 on Forms S-8 of Harvard Apparatus Regenerative Technology, Inc. of our report dated March 30, 2016, with respect to the consolidated balance sheets of Harvard Apparatus Regenerative Technology, Inc. and subsidiaries as of December 31, 2015 and 2014, and the related consolidated statements of operations and comprehensive loss, stockholders’ equity and cash flows for each of the years in the two-year period ended December 31, 2015, which report appears in the December 31, 2015 annual report on Form 10-K of Harvard Apparatus Regenerative Technology, Inc.
Our report dated March 30, 2016 contains an explanatory paragraph that states that the Company has suffered recurring losses from operations and will require additional financing to fund future operations which raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.
(Signed) KPMG LLP
Boston, Massachusetts
March 30, 2016